Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05118633

Technology Assisted Treatment for Trichotillomania

The investigators are testing two digital health interventions for trichotillomania (TTM), via a randomized trial design.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Psychological Sciences

Kent, Ohio, 44242, United States

Location status: Recruiting

Location contact

Christopher Flessner, PhD

CONTACT

[email protected]

(330) 672-2200

About this study

Trichotillomania is characterized by recurrent hair pulling despite repeated attempts to stop, resulting in hair loss as well as significant distress and impairment. Behavior therapies focused on increasing awareness of hair pulling followed by the use of an incompatible behavior (i.e., competing response) and other behavioral strategies (e.g., stimulus control) are efficacious. In this randomized control trial, we are testing the preliminary efficacy of two digital health interventions for adults with TTM (N=90). Participants will be randomly assigned (50/50 chance) to receive 8 weeks of (a) a digital behavior therapy that includes a wrist worn motion detection device to enhance awareness and a companion mobile application that provides psychoeducation, awareness training (e.g., self-monitoring), and behavioral strategy suggestions or (b) a digital general wellness intervention that includes a reminder bracelet (i.e., a wrist-worn visual reminder not to pull) accompanied by a smartphone app that includes general context logging and delivery of general health tips.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older (criterion 1a) with a diagnosis of TTM focused on primary hair pulling location(s) above the neck (e.g., scalp, eyebrows, eye lashes, beard) (criterion 1b).
  • English language fluency (criterion 2).
  • Report no current pharmacological intervention targeting TTM symptoms OR a 6-week course of the intervention without change in dosage and intent for that dosage to remain stable for the 12 weeks of this trial (criterion 3a).
  • Report no current psychosocial intervention targeting TTM (criterion 3b)
  • Reliable and consistent access to the internet and/or mobile device permitting the participant to meet with someone virtually for 90 min.
  • Owns a mobile phone running on Apple's operating system (iOS 6+) 6. Identifies a support person that is able to be contacted if an emergency arises.

Exclusion criteria

  • Current suicidal/homicidal ideation, intent, or plan (criterion 1a) or a diagnosis of another psychiatric condition that may impede a participant's ability to fully utilize the app (e.g., psychotic disorder, eating disorder, moderate to severe major depressive disorder [defined by meeting diagnostic criteria on the MINI and a score >13 on DASS-21]) (criterion 1b)
  • Has not used HabitAware's Keen or Keen2 bracelet in the past 24 months.
  • Residing outside the United States

Treatment and study plan

Keen2 bracelet

Device

Participants will receive an awareness bracelet (Keen2) which vibrates upon detection of hair pulling motion, supporting behavior therapy for hair pulling delivered by the Keen2 app.

Reminder bracelet

Device

Participants will receive a non-vibrating bracelet to wear as a visual reminder not to pull.

Keen2 app

Behavioral

Participants will be given access to a smartphone app. The bracelet and app work together to implement key features of habit reversal training for TTM, including psychoeducation, awareness training, competing response training, and personalized just-in-time stimulus control and other behavioral strategy reminders.

Health Reminders App

Behavioral

Participants will be given access to a smartphone app that will prompt them to log their context (e.g., location and activity) throughout the day and provide general health tips.

Primary outcomes

  1. Clinician-rated trichotillomania (TTM) symptom severity at endpoint (week 8)

    Time frame: Eight weeks

    Scores on the NIMH Trichotilomania Severity Scale (NIMH-TSS), a clinician-administered assessment of TTM symptom severity, will be compared across conditions at endpoint (week 8), controlling for baseline severity. The NIMH-TSS is a 5-item clinician rated measure of TTM severity ranging from 0-25, with higher scores indicating more severe symptoms.

Secondary outcomes

  1. Self-reported trichotillomania (TTM) severity at endpoint (week 8)

    Time frame: 8 weeks

    Scores on the Massachusetts General Hospital Hair Pulling Scale (MGH-HS), a validated and widely used 7-item Likert self-report measure of TTM symptom severity, will be compared across conditions at endpoint (week 8), controlling for baseline severity. MGH-HS scores range from 0 to 28, with higher scores corresponding with more severe TTM symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Sameer Kumar, BS

CONTACT

[email protected]

248-990-4720

Sponsors and collaborators

Lead sponsor

HabitAware Inc.

Industry

Collaborators

  • Kent State University

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Nov 12, 2021
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.